-A Technology Integration for MEDISAFE WITH™ Insulin Patch Pump Patients to 
Upload Data Anytime Anywhere

Terumo Corporation (TSE: 4543), a global leader in medical technology, and 
Glooko, a global leader in data management, remote patient monitoring and 
mobile apps for people with chronic conditions, have announced a technology 
integration to deliver new diabetes data sharing solutions together globally. 
This new integration will enable people with diabetes to transfer recorded data 
from MEDISAFE WITH™ insulin patch pump into the Glooko platform, thus helping 
them to visualize insulin dosage, food, and activities in graphs more easily 
and to realize personalized remote patient monitoring and patient care more 
effectively.

Available in Europe from May 2022, the two companies will start offering this 
new diabetes data solution, enabling patients to share their data with 
healthcare professionals easily both in the physicians' office and remotely 
from home. This integration will allow healthcare professionals to view the 
patient's latest health records more frequently, in-person at the clinic or 
remotely via Glooko's analytics portal.

Additionally, as a next step, both companies are working on a unique way of 
transferring recorded data from the MEDISAFE WITH™ insulin patch pump to the 
Glooko Mobile App directly via NFC (near field communication), which is planned 
to be launched in Europe later this year. MEDISAFE WITH™ will be the world's 
first insulin patch pump with direct NFC connection to the Glooko Mobile App, 
utilizing patients' personal smart phones to share their diabetes data with 
their diabetes team anytime, anywhere.

"We are excited to announce this new patient-focused collaboration with Glooko. 
These new solutions will allow people with diabetes to upload their data from 
home easily without the need to visit the hospital. We believe this is a 
valuable solution for both patients and healthcare providers especially under 
the post COVID-19 'new normal' lifestyle," commented Hikaru Samejima, President 
of Terumo's General Hospital Company.

Terumo has been a player in the diabetes market for approximately 40 years, 
since 1982, providing a wide range of products globally such as insulin 
injection needles, blood glucose meters and insulin pumps. In November 2020, 
Terumo obtained CE mark for MEDISAFE WITH™, and is expanding its product 
availability globally. Currently, Glooko's solutions are used in 31 countries, 
digitally connecting people with diabetes and their healthcare professional 
teams. This integration enables more timely information sharing and more 
powerful remote patient management for better care.

Russ Johannesson, Chief Executive Officer for Glooko stated, "Our continued 
partnership with Terumo means even more access to health data for people with 
diabetes and their healthcare providers. We are very pleased to expand our 
partnership with Terumo by integrating Glooko's data management and remote 
patient monitoring platform with the MEDISAFE WITH™ insulin patch pump. This 
means people with diabetes will be able to make more informed decisions with 
their data, and collaborate with their health care team. That data includes 
insulin, glucose, diet, activity and blood pressure.  Having the best 
connectivity is imperative for delivering world class care, so we are happy to 
partner with Terumo to integrate its new insulin patch pump."

About Glooko

Glooko is transforming digital health by connecting people with diabetes and 
other chronic conditions with their healthcare teams, enabling collaborative 
telehealth, clinical research and improved health outcomes. The company's 
software platforms collect and analyze data from multiple devices in one highly 
secure place, allowing for easy remote upload via app or in-clinic, and 
producing easy-to-read analytics through actionable charts and graphs. The 
platform is compatible with over 95% of global diabetes and health monitoring 
devices, giving patients and their providers flexibility in how to manage their 
conditions. With over 35B+ data points, Glooko is the global leader in diabetes 
patient data. More than 3 million users have already benefited from Glooko's 
solutions in 31 countries across 22 languages. Learn more at glooko.com

About Terumo

Terumo (TSE:4543) is a global leader in medical technology and has been 
committed to "Contributing to Society through Healthcare" for more than 100 
years. Based in Tokyo and operating globally, Terumo employs more than 25,000 
associates worldwide to provide innovative medical solutions in more than 160 
countries and regions. The company started as a Japanese thermometer 
manufacturer and has been supporting healthcare ever since. Now, its extensive 
business portfolio ranges from vascular intervention and cardio-surgical 
solutions, blood transfusion and cell therapy technologies, to medical products 
essential for daily clinical practice such as transfusion systems, diabetes 
care, and peritoneal dialysis treatments. Terumo will further strive to be of 
value to patients, medical professionals, and society at large.

SOURCE: Terumo


Image Attachments Links:

   Link: https://iop.asianetnews.net/view-attachment?attach-id=418063

   Caption: Patient wearing MEDISAFE WITH

   Link: https://iop.asianetnews.net/view-attachment?attach-id=418064

   Caption: MEDISAFE WITH

   Link: https://iop.asianetnews.net/view-attachment?attach-id=418065

   Caption: Patient uploading solution

   Link: https://iop.asianetnews.net/view-attachment?attach-id=418066

   Caption: Direct connect to mobile app